Oct 29, 2024 7:00 am EDT Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Oct 21, 2024 7:00 am EDT Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
Sep 23, 2024 7:00 am EDT Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
Aug 26, 2024 7:00 am EDT Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
Aug 22, 2024 7:00 am EDT Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Aug 9, 2024 5:59 pm EDT Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Jul 24, 2024 6:00 am EDT Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints